P035 Inflammatory myopathy and metabolic disorders causing myopathies
Conclusion This lady was initially managed as inflammatory myopathy but did not respond to high dose methylprednisolone. There were atypical features including normal inflammatory markers, MRI thighs showing predominantly fatty infiltration and muscle atrophy and the muscle biopsy with abundant lipid accumu lation suggestive of a metabolic disorder. We are awaiting full results of genetic testing. This case is a reminder of the importance of tissue diagnosis and reassessing the initial diagnosis if the clinical picture changes or patients do not respond as expected to treatment.Disclosure M. Malik: None.A. Mason: None....
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
P020 A new complex musculoskeletal clinic combining rheumatology and sport and exercise medicine services
Conclusion This report illustrates the spectrum of diagnoses seen within this unique service, highlighting a role for both Rheumatology and SEM within the same clinic. The low onward referral rate demonstrates appropriate triage and an efficient approach that is appropriate for this cohort of patients. It c ould reduce overall costs and patient journeys. Further work is required to streamline patient pathways, evaluate patient satisfaction and to determine whether the clinic is cost-effective and improves patient pathways.Disclosure J.A. Navarajasegaran: None.J. Betts: None.J. Baldock: None.A. Soni: None.R. Smith: None...
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
P019 Audit of prostanoid use in severe Raynaud’s and adherence to treatment of digital ulcers in patients with SSc NHSE pathway: commissioning policy cost analysis and alternative therapeutic pathway proposed
Conclusion Epoprostenol is used in our unit for patients with severe RP from a range of conditions. Sildenafil and CCB have been trialled in the majority of our patients prior to escalation. Only a minority of patients have received bosentan according to current guidelines and licensing. Given the reduction in cost, combined with the importance of avoiding hospital admissions with COVID-19, we would suggest that bosentan could be used earlier in the treatment pathway for a broader range of indications. NHSE is revising the SSc commissioning policy.Disclosure A. Young: None.B. Griffiths: None.J. Vila: None. (Source: Rheumatology)
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
P018 Multi-disciplinary team management of haemophagocytic lymphohistiocytosis: improving patient outcomes in a central London teaching hospital
Conclusion We believe that the HLH MDT has directly contributed to these improvements by encouraging earlier recognition and subspeciality collaboration. We encourage other sites to adopt a multi-disciplinary approach to managing patients with HLH to promote awareness of the condition and improve patient ou tcomes.Disclosure D.R. Ludwig: None.J. Manson: None.A. Jones: None.S. Mackenzie: None.N. Mccann: None. (Source: Rheumatology)
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
P017 Out of outlier status: local observations from the National Early Inflammatory Arthritis Audit
Conclusion Significant changes have been made which have resulted in an improvement in performance against QS2 and 3. Disease activity at baseline was lower, potentially as a result of seeing patients sooner and this has resulted in better outcomes for patients at 3 months. Ongoing data collection will allo w the team to determine outcomes at 12 months.Disclosure E. MacPhie: Other; EM is the secretary of the North West Rheumatology Club, these regional meetings have been funding by an unrestricted educational grant from UCB and are now sponsored by Abbvie.L. Ashcroft: None.J. Brazendale: None.N. Foreman: None.S. Gilber...
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
